ResMed Inc. (RMD) fair value analysis

S&P 500 · Updated 2026-09-07

ResMed Inc. is a global healthcare company that develops and manufactures cloud-connected medical devices and software solutions, primarily serving patients with chronic respiratory diseases, sleep apnea, and other out-of-home care needs. The company operates across multiple regions worldwide, including North America, Europe, and Asia-Pacific, serving hospitals, home healthcare providers, and individual patients through its diversified product portfolio.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, RMD is trading at more than a 25% discount to estimated fair value.

RMD currently ranks #24 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $228.35
Sector: Healthcare
12-month range: $186.44–$257.39

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Momentum grade: B
Leverage: Low
Margin trend: Expanding
Revenue growth: Strong
RSI zone: Neutral
52-week position: The upper-middle quarter of its range
DCF cross-check: Fairly Valued

What our data shows for RMD

Our model validated 17 trailing price-to-earnings windows for RMD, built from quarterly earnings records.
Shares are trading in the middle of their 12-month price range of $186.44–$257.39.
The 14-day relative strength index sits at a neutral 50.
3 of the last 12 weekly snapshots showed positive price momentum.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for RMD
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent RMD news

TickrTrends' derived news-sentiment signal for RMD is currently leaning positive, computed from recent coverage.

QAN shares: your next growth investment? (raskmedia.com.au, 2026-09-07)
TickrTrends take: RespiMed (RMD) operates in the Healthcare sector where TickrTrends currently identifies it as undervalued based on its derived analysis. The valuation assessment suggests that investors focused on fundamental value metrics may find the current pricing presents an opportunity relative to the company's underlying metrics. Readers monitoring RMD's valuation should track how the company's financial performance and market conditions evolve relative to this undervalued positioning.
A deep dive into RMD shares (raskmedia.com.au, 2026-09-02)
TickrTrends take: ResMed Inc operates in the Healthcare sector where consistent profitability and revenue growth typically support higher valuations, yet TickrTrends currently identifies RMD as undervalued based on its analytical framework. For valuation-focused investors, this suggests the current market price may not fully reflect the company's fundamental value or growth prospects in its industry segment. Readers should monitor whether RMD's upcoming financial results and operational metrics narrow any gaps between its market valuation and intrinsic value estimates.
RMD Maintained by Keybanc -- Price Target Raised to $267 (gurufocus.com, 2026-08-31)
TickrTrends take: Keybanc's decision to maintain its stance on RMD while raising the price target to $267 suggests analyst confidence in the company's fundamental trajectory within the Healthcare sector. Given TickrTrends' current assessment that RMD trades at an undervalued level, the raised price target may reflect growing conviction that the market has not fully priced in the company's earnings potential or competitive positioning. Valuation-focused investors should monitor whether RMD's actual trading price moves toward the $267 target, as this would indicate whether the current undervaluation thesis is closing.

What people are saying

Follow the RMD conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — RMD's valuation indicators shifted this week as the DCF cross-check band moved from overvalued to fairly valued territory. The Healthcare sector stock maintains an undervalued verdict from TickrTrends' derived indicators, suggesting a potential disconnect between the DCF assessment and the broader valuation analysis.
2026-09-06 — TickrTrends' derived indicators for RMD show a shift in momentum from A to B this week. The stock maintains an undervalued position according to current valuation metrics. This change in momentum warrants monitoring as the stock continues to be evaluated within the Healthcare sector.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is RMD stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), RMD is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is RMD's TickrTrends verdict?

RMD's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does RMD compare to other Healthcare stocks?

RMD ranks #24 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is RMD overbought or oversold?

RMD's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

RMD vs AVAH · RMD vs DXCM · RMD vs HQY · RMD vs HSTM · RMD vs IDXX